The alert follows a wave of warning letters the agency sent to Supergoop!, Vacation Inc. and three other popular brands, ...

Federal health officials are warning sunscreen companies for violating drug regulations by selling products in unapproved ...

Net loss (GAAP) narrowed to $6.1 million in Q2 2025, a 22.8% improvement from the prior-year period, driven by reduced research and development spending. No product revenue reported; The company’s ...

Leadership and talent actions -- Lisa Wolf confirmed as CFO; key hires from Statera joined for regulatory, clinical, and ...

The Vicksburg Police Department is accepting applications for entry-level officer positions. The department said it offers a ...

The expedited approval of mpox vaccines is critical to addressing this public health emergency. Building on the practice in approving COVID-19 vaccines, this analysis investigates the regulatory ...

MAXONA Pharmaceuticals has taken a key step toward advancing its flagship pain therapy, filing an Investigational New Drug ...

Researchers from Simon Fraser University have unveiled an artificial intelligence framework that could transform drug ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...

A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.

Dr. Aaron Gerds explained when treatment with rusfertide will become accessible for patients with a myeloproliferative neoplasm like polycythemia vera.

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and ...